Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Lgals9 deficiency ameliorates obesity by modulating redox state of PRDX2

Nunoue T., Yamaguchi S., Teshigawara S., Katayama A., Nakatsuka A., Eguchi J.

Animal Study on Chronic Inflammation, published in Sci Rep (2021) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Sci Rep (2021)
Reported sample size
—
Source database
Europe PMC
PMID
33727589
PMCID
PMC7966757
DOI
10.1038/s41598-021-85080-1
Citations
5

Abstract (original English)

The adipose tissue is regarded as an endocrine organ and secretes bioactive adipokines modulating chronic inflammation and oxidative stress in obesity. Gal-9 is secreted out upon cell injuries, interacts with T-cell immunoglobulin-3 (Tim-3) and induces apoptosis in activated Th1 cells. Gal-9 also binds to protein disulfide isomerase (PDI), maintains PDI on surface of T cells, and increases free thiols in the disulfide/thiol cycles. To explore the molecular mechanism of obesity, we investigated Gal-9 -/- and Gal-9 wt/wt C57BL/6J mice fed with high fat-high sucrose (HFHS) chow. Gal-9 -/- mice were resistant to diet-induced obesity associated with reduction of epididymal and mesenteric fat tissues and improved glucose tolerance compared with Gal-9 wt/wt mice. However, the number of M1, M2 macrophages, and M1/M2 ratio in epididymal fat were unaltered. Under HFHS chow, Gal-9 -/- mice receiving Gal-9 -/- or Gal-9 wt/wt bone marrow-derived cells (BMCs) demonstrated significantly lower body weight compared with Gal-9 wt/wt mice receiving Gal-9 -/- BMCs. We identified the binding between Gal-9 and peroxiredoxin-2 (PRDX2) in sugar chain-independent manner by nanoLC-MS/MS, immunoprecipitation, and pull-down assay. In 3T3L1 adipocytes, Gal-9 knockdown shifts PRDX2 monomer (reduced form) dominant from PRDX2 dimer (oxidized form) under oxidative stress with H 2 O 2 . The inhibition of Gal-9

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
LiverAdipose TissueAnimalsMice, KnockoutMiceObesityDisease Models, AnimalDisease SusceptibilityBody WeightGlucose

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research